DOCSLIB.ORG

Anatte Margalit, B.Sc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anatte Margalit, B.Sc Analysis of the interactions between Aspergillus fumigatus, Pseudomonas aeruginosa and a model of the alveolar surface A thesis submitted to Maynooth University for the degree of Doctor of Philosophy Anatte Margalit, B.Sc October 2019 Supervisor Co-supervisor Head of Department Prof. Kevin Kavanagh Dr. James C. Carolan Prof. Paul Moynagh Medical Mycology Applied Proteomics Dept. of Biology Laboratory Laboratory Maynooth University Department of Biology Department of Biology Maynooth University Maynooth University Chapter 1 Introduction .............................................................................................................. 1 1.1 Cystic fibrosis ..................................................................................................................... 2 1.1.1 The microbial environment of the CF airways ............................................................ 3 1.1.2 Impact of polymicrobial infections in CF .................................................................... 6 1.1.3 Advances in therapy for cystic fibrosis ........................................................................ 7 1.1.4 The microbial environment in non-cystic fibrosis-related conditions.......................... 9 1.2 Study of polymicrobial interactions .................................................................................. 11 1.3 In vitro models for the study of pathogen host interactions of the lung............................ 13 1.4 The A549 cell line as a model for infection at the alveolar surface .................................. 14 1.5 Aspergillus fumigatus; an opportunistic human pathogen ................................................ 15 1.5.1 A. fumigatus pathogenesis and host – from inhalation to germination ...................... 16 1.5.1.1 Host cell recognition of A. fumigatus ...................................................................... 17 1.5.1.2 The humoral response to A. fumigatus .................................................................... 18 1.5.1.3 Manipulation of host epithelial cells by A. fumigatus ............................................. 19 1.5.1.4 The innate immune cell response to A. fumigatus ................................................... 20 1.5.1.5 The adaptive immune response to A. fumigatus ...................................................... 22 1.5.3 Impact of A. fumigatus on cystic fibrosis patients ..................................................... 25 1.5.4 Microbial interactions involving A. fumigatus ........................................................... 27 1.6 Pseudomonas aeruginosa: an opportunistic human pathogen ...................................... 28 1.6.1 The host immune response to P. aeruginosa ............................................................. 30 1.6.1.1 The mucociliary elevator ........................................................................................ 30 1.6.1.3 Host cellular receptors to detect P. aeruginosa ...................................................... 32 1.6.1.4 Cellular response to P. aeruginosa ......................................................................... 33 1.6.2 P. aeruginosa virulence factors ................................................................................. 35 1.6.2.1 Flagella and Type IV Pili ........................................................................................ 35 1.6.2.2 Type III secretion systems ...................................................................................... 35 1.6.2.3 P. aeruginosa Biofilms and Quorum sensing ......................................................... 36 1.6.3 P. aeruginosa acute airway pathogenesis .................................................................. 37 1.6.4 Pathogenesis of P. aeruginosa in chronic airway conditions..................................... 37 1.6.5 Adaptation and colonization of P. aeruginosa in the CF lung ................................... 38 1.6.6 Microbial interactions involving P. aeruginosa ......................................................... 38 1.7 Interactions between A. fumigatus and P. aeruginosa ...................................................... 40 1.7.1 Antagonistic interactions between A. fumigatus and P. aeruginosa .......................... 41 1.7.2 Synergistic interactions between A. fumigatus and P. aeruginosa ............................ 42 1.8 Antimicrobial resistance in P. aeruginosa ....................................................................... 43 1.9 Novel antimicrobial drug discovery; approaches and challenges ..................................... 44 i 1.10 Choosing proteomics to investigate inter-species interactions ....................................... 45 1.10.1 Label-free quantitative proteomics .......................................................................... 46 1.10.2 The application of LFQ proteomics for investigating inter-species interactions ..... 47 1.11 Overview of thesis objectives ......................................................................................... 48 Chapter 2 Materials and Methods .................................................................................. 50 2.1 General Chemicals and Reagents ...................................................................................... 51 2.1.1 Phosphate Buffered Saline (PBS) .............................................................................. 51 2.1.1.2 PBS-Tween 80 (PBST) ........................................................................................... 51 2.1.2 Solutions for pH Adjustment ..................................................................................... 51 2.1.2.1 Hydrochloric Acid (HCl) (5 M) .............................................................................. 51 2.1.2.2 Sodium Hydroxide (NaOH) (5 M) .......................................................................... 51 2.2 Maintenance and preparation of P. aeruginosa ................................................................ 52 2.2.1 Bacterial culture media .............................................................................................. 52 2.2.2 Super Optimal Broth with catabolite repression (SOC medium); SOC agar (0.3%) . 52 2.2.3 Synthetic Cystic Fibrosis Medium (SCFM) ............................................................... 53 2.2.4 Maintenance of P. aeruginosa ................................................................................... 53 2.2.4.1 Preparation of P. aeruginosa in cell culture medium.............................................. 53 2.2.5 Bacterial toxicity assays ............................................................................................. 54 2.3 Maintenance and preparation of A. fumigatus................................................................... 54 2.3.1 Aspergillus culture media (Czapek-Dox) ................................................................... 54 2.3.2 Aspergillus culture media (Sabouraud) ...................................................................... 54 2.3.3 Minimal Medium Broth ............................................................................................. 55 2.3.4 Culture and maintenance of A. fumigatus .................................................................. 55 2.3.4.1 Preparation of A. fumigatus conidia in mammalian cell culture medium ............... 55 2.3.5 Culture and maintenance of A. flavus and A. nidulans............................................... 56 2.3.5.1 Media preparation ................................................................................................... 56 2.3.6 Culture and maintenance of A. flavus ........................................................................ 56 2.3.7 Culture and maintenance of A. nidulans .................................................................... 56 2.3.8 A. fumigatus culture filtrate and P. aeruginosa culture filtrates ................................ 56 2.3.8.1 A. fumigatus and P. aeruginosa co-culture culture filtrates .................................... 57 2.3.8.2 Exposure of A. fumigatus to culture filtrates ........................................................... 57 2.3.8.3 Exposure of P. aeruginosa to culture filtrates ........................................................ 57 2.4 A549 Cell culture medium and maintenance .................................................................... 58 2.4.1 Cell culture medium ................................................................................................... 58 2.4.2 Cryporeservation buffer ............................................................................................. 58 2.4.3 Maintenance and sub-culturing .................................................................................. 58 ii 2.4.4 Cryopreservation of A549 cells in Liquid Nitrogen .................................................. 59 2.4.5 Recovery of A549 cells from Liquid Nitrogen .......................................................... 59 2.4.6 Exposure of A549 cells to A. fumigatus and/or P. aeruginosa for 12 hours .............. 59 2.4.7 Sequential Exposure of A549 cells to A. fumigatus and P. aeruginosa ..................... 60 2.5 Protein extraction .............................................................................................................. 60 2.5.1 Lysis buffer/Resuspension buffer .............................................................................. 60 2.5.2 Protein quantification by Bradford protein assay ......................................................
Load more

Recommended publications
  • A Theoretical Study of the Tryptophan Synthase Enzyme Reaction Network
    A Theoretical Study of the Tryptophan Synthase Enzyme Reaction Network Dissertation zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) im Fach Chemie Spezialisierung: Physikalische und theoretische Chemie Eingereicht an der Mathematisch-Naturwissenschaftlichen Fakult¨at der Humboldt-Universit¨at zu Berlin von Dimitri Loutchko Pr¨asidentin der Humboldt-Universit¨atzu Berlin Prof. Dr.-Ing. Dr. Sabine Kunst Dekan der Mathematisch-Naturwissenschaftlichen Fakult¨at Prof. Dr. Elmar Kulke 1. Gutachter: Prof. Dr. Gerhard Ertl 2. Gutachter: Prof. Dr. Klaus Rademann 3. Gutachter: Prof. Dr. Yannick de Decker Tag der m¨undlichen Pr¨ufung:09.07.2018 ii Abstract iii Abstract The channeling enzyme tryptophan synthase provides a paradigmatic example of a chemical nanomachine. It catalyzes the biosynthesis of tryptophan from serine and indole glycerol phos- phate. As a single macromolecule, it possesses two distinct catalytic subunits and implements 13 different elementary reaction steps. A complex pattern of allosteric regulation is involved in its operation. The catalytic activity in a subunit is enhanced or inhibited depending on the state of the other subunit. The gates controlling arrival and release of the ligands can become open or closed depending on the chemical states. The intermediate product indole is directly channeled within the protein from one subunit to another, so that it is never released into the solution around it. In this thesis, the first single-molecule kinetic model of the enzyme is proposed and analyzed. All its transition rate constants are extracted from available experimental data, and thus, no fitting parameters are employed. Numerical simulations reveal strong correlations in the states of the active centers and the emergent synchronization of intramolecular processes in tryptophan synthase.
    [Show full text]
  • Purification, Crystallization and Preliminary X-Ray Diffraction Analysis of Exodeoxyribonuclease III from Crenarchaeon Sulfolobus Tokodaii Strain 7
    Crystal Structure Theory and Applications, 2013, 2, 155-158 Published Online December 2013 (http://www.scirp.org/journal/csta) http://dx.doi.org/10.4236/csta.2013.24021 Purification, Crystallization and Preliminary X-Ray Diffraction Analysis of Exodeoxyribonuclease III from Crenarchaeon Sulfolobus tokodaii Strain 7 Shuichi Miyamoto1*, Chieko Naoe2, Masaru Tsunoda3, Kazuo T. Nakamura2 1Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan 2School of Pharmacy, Showa University, Tokyo, Japan 3Faculty of Pharmacy, Iwaki Meisei University, Iwaki, Japan Email: *[email protected] Received October 13, 2013; revised November 12, 2013; accepted December 6, 2013 Copyright © 2013 Shuichi Miyamoto et al. This is an open access article distributed under the Creative Commons Attribution Li- cense, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Exodeoxyribonuclease III (EXOIII) acts as a 3’→5’ exonuclease and is homologous to purinic/apyrimidinic (AP) en- donuclease (APE), which plays an important role in the base excision repair pathway. To structurally investigate the reaction and substrate recognition mechanisms of EXOIII, a crystallographic study of EXOIII from Sulfolobus tokodaii strain 7 was carried out. The purified enzyme was crystallized by using the hanging-drop vapor-diffusion method. The crystals belonged to space group C2, with unit-cell parameters a = 154.2, b = 47.7, c = 92.4 Å, β = 125.8˚ and diffracted to 1.5 Å resolution. Keywords: Crenarchaeon; Crystallization; Exodeoxyribonuclease; Sulfolobus tokodaii; X-Ray Diffraction 1. Introduction formational change upon protein binding that permits complex formation and activation of attacking water, A variety of mechanisms exist to repair damaged DNA leading to incision, in the presence of Mg2+ [10,11].
    [Show full text]
  • The Rnase H-Like Superfamily: New Members, Comparative Structural Analysis and Evolutionary Classification Karolina A
    4160–4179 Nucleic Acids Research, 2014, Vol. 42, No. 7 Published online 23 January 2014 doi:10.1093/nar/gkt1414 The RNase H-like superfamily: new members, comparative structural analysis and evolutionary classification Karolina A. Majorek1,2,3,y, Stanislaw Dunin-Horkawicz1,y, Kamil Steczkiewicz4, Anna Muszewska4,5, Marcin Nowotny6, Krzysztof Ginalski4 and Janusz M. Bujnicki1,3,* 1Laboratory of Bioinformatics and Protein Engineering, International Institute of Molecular and Cell Biology, ul. Ks. Trojdena 4, PL-02-109 Warsaw, Poland, 2Department of Molecular Physiology and Biological Physics, University of Virginia, 1340 Jefferson Park Avenue, Charlottesville, VA USA-22908, USA, 3Bioinformatics Laboratory, Institute of Molecular Biology and Biotechnology, Adam Mickiewicz University, Umultowska 89, PL-61-614 Poznan, Poland, 4Laboratory of Bioinformatics and Systems Biology, Centre of New Technologies, University of Warsaw, Zwirki i Wigury 93, PL-02-089 Warsaw, Poland, 5Institute of Biochemistry and Biophysics PAS, Pawinskiego 5A, PL-02-106 Warsaw, Poland and 6Laboratory of Protein Structure, International Institute of Molecular and Cell Biology, ul. Ks. Trojdena 4, PL-02-109 Warsaw, Poland Received September 23, 2013; Revised December 12, 2013; Accepted December 26, 2013 ABSTRACT revealed a correlation between the orientation of Ribonuclease H-like (RNHL) superfamily, also called the C-terminal helix with the exonuclease/endo- the retroviral integrase superfamily, groups together nuclease function and the architecture of the numerous enzymes involved in nucleic acid metab- active site. Our analysis provides a comprehensive olism and implicated in many biological processes, picture of sequence-structure-function relation- including replication, homologous recombination, ships in the RNHL superfamily that may guide func- DNA repair, transposition and RNA interference.
    [Show full text]
  • Bronchiectasis (Non-Cystic Fibrosis), Acute Exacerbation: Antimicrobial Prescribing Evidence Review
    N ational Institute for Health and Care Excellence Final Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing Evidence review NICE guideline NG117 December 2018 Final Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties. NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive. All NICE guidance is subject to regular review and may be updated or withdrawn. Copyright © National Institute for Health and Care Excellence, 2018. All rights reserved.
    [Show full text]
  • Directed Evolution of the Tryptophan Synthase Β-Subunit for Stand-Alone Function Recapitulates Allosteric Activation
    Directed evolution of the tryptophan synthase β-subunit for stand-alone function recapitulates allosteric activation Andrew R. Buller1, Sabine Brinkmann-Chen1, David K. Romney, Michael Herger, Javier Murciano-Calles, and Frances H. Arnold2 Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125 Edited by Alan R. Fersht, Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom, and approved October 16, 2015 (received for review August 17, 2015) Enzymes in heteromeric, allosterically regulated complexes cata- associated with open, partially closed, and fully closed states lyze a rich array of chemical reactions. Separating the subunits of during the catalytic cycle (2, 4, 6). such complexes, however, often severely attenuates their catalytic TrpS is a naturally promiscuous enzyme complex: the model activities, because they can no longer be activated by their protein system from S. typhimurium catalyzes its β-substitution reaction partners. We used directed evolution to explore allosteric regula- with most haloindoles, methylindoles, and aminoindoles, along tion as a source of latent catalytic potential using the β-subunit of with an assortment of nonindole nucleophiles for C–S, C–N, and – tryptophan synthase from Pyrococcus furiosus (PfTrpB). As part of C C bond formation (7). Such noncanonical amino acids (NCAAs) its native αββα complex, TrpB efficiently produces tryptophan and have diverse applications in chemical biology (8), serve as inter- tryptophan analogs; activity drops considerably when it is used as mediates in the synthesis of natural products (9, 10), and are priv- a stand-alone catalyst without the α-subunit. Kinetic, spectro- ileged scaffolds for the development of pharmaceuticals (11).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew Et Al
    US009314465B2 (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew et al. (45) Date of Patent: *Apr. 19, 2016 (54) DRUG COMBINATIONS AND USES IN 2008.0003280 A1 1/2008 Levine et al. ................. 424/456 TREATING A COUGHING CONDITION 2008/O176955 A1 7/2008 Hecket al. 2008, 0220078 A1 9, 2008 Morton et al. (71) Applicant: Infirst Healthcare Limited 2009, O136427 A1 5/2009 Croft et al. 2009, O220594 A1 9, 2009 Field (72) Inventors: John Brew, London (GB); Robin Mark 2012/O128738 A1 5, 2012 Brew et al. Bannister, London (GB) 2012fO252824 A1 10/2012 Brew et al. (73) Assignee: Infirst Healthcare Limited, London FOREIGN PATENT DOCUMENTS (GB) CN 1593451 3, 2005 CN 101024.014 A 8, 2007 (*) Notice: Subject to any disclaimer, the term of this CN 101112383 B 5, 2010 patent is extended or adjusted under 35 DE 4420708 A1 12, 1995 U.S.C. 154(b) by 0 days. EP 2050435 B1 4/2009 GB 2114001 A 8, 1983 This patent is Subject to a terminal dis GB 2284761 A 6, 1995 claimer. GB 2424.185 B 9, 2006 GB 2442828 A 4/2008 JP 62-249924 A 10, 1987 (21) Appl. No.: 14/287,014 JP H1O-316568 A 12/1998 JP 2001-518928 A 10, 2001 (22) Filed: May 24, 2014 JP 200219.3839. A T 2002 JP 2003-012514 A 1, 2003 (65) Prior Publication Data JP 20030552.58 A 2, 2003 JP 2003128549 A 5, 2003 US 2014/O256750 A1 Sep. 11, 2014 JP 2003-321357 A 11, 2003 JP 2005-516917 A 6, 2005 JP 2008O31146 A 2, 2008 Related U.S.
    [Show full text]
  • Supplementary Materials
    Supplementary Materials COMPARATIVE ANALYSIS OF THE TRANSCRIPTOME, PROTEOME AND miRNA PROFILE OF KUPFFER CELLS AND MONOCYTES Andrey Elchaninov1,3*, Anastasiya Lokhonina1,3, Maria Nikitina2, Polina Vishnyakova1,3, Andrey Makarov1, Irina Arutyunyan1, Anastasiya Poltavets1, Evgeniya Kananykhina2, Sergey Kovalchuk4, Evgeny Karpulevich5,6, Galina Bolshakova2, Gennady Sukhikh1, Timur Fatkhudinov2,3 1 Laboratory of Regenerative Medicine, National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov of Ministry of Healthcare of Russian Federation, Moscow, Russia 2 Laboratory of Growth and Development, Scientific Research Institute of Human Morphology, Moscow, Russia 3 Histology Department, Medical Institute, Peoples' Friendship University of Russia, Moscow, Russia 4 Laboratory of Bioinformatic methods for Combinatorial Chemistry and Biology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia 5 Information Systems Department, Ivannikov Institute for System Programming of the Russian Academy of Sciences, Moscow, Russia 6 Genome Engineering Laboratory, Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region, Russia Figure S1. Flow cytometry analysis of unsorted blood sample. Representative forward, side scattering and histogram are shown. The proportions of negative cells were determined in relation to the isotype controls. The percentages of positive cells are indicated. The blue curve corresponds to the isotype control. Figure S2. Flow cytometry analysis of unsorted liver stromal cells. Representative forward, side scattering and histogram are shown. The proportions of negative cells were determined in relation to the isotype controls. The percentages of positive cells are indicated. The blue curve corresponds to the isotype control. Figure S3. MiRNAs expression analysis in monocytes and Kupffer cells. Full-length of heatmaps are presented.
    [Show full text]
  • Pharmacotherapy of Impaired Mucociliary Clearance in Non-CF Pediatric Lung Disease
    Pediatric Pulmonology 42:989–1001 (2007) State of the Art Pharmacotherapy of Impaired Mucociliary Clearance in Non-CF Pediatric Lung Disease. A Review of the Literature 1 1 1,2 Ruben Boogaard, MD, * Johan C. de Jongste, MD, PhD, and Peter J.F.M. Merkus, MD, PhD Summary. Mucoactive agents are used to treat a variety of lung diseases involving impaired mucociliary clearance or mucus hypersecretion. The mucoactive agents studied most frequently are N-acetylcysteine (NAC), recombinant human DNase (rhDNase), and hypertonic saline. Studies on the efficacy of these have been mainly conducted in adults, and in patients with cystic fibrosis (CF). The exact role of mucoactive agents in children with non-CF lung disease is not well established. We present an overview of the current literature reporting clinical outcome measures of treatment with NAC, rhDNase, and hypertonic saline in children. Pediatr Pulmonol. 2007; 42:989–1001. ß 2007 Wiley-Liss, Inc. Key words: mucolytic; sulfhydryl compounds; N-acetylcysteine; dornase alfa; hyper- tonic saline; respiratory tract disease. INTRODUCTION One possible means to evaluate a mucoactive agent is to assess its effect on mucociliary clearance (MCC) or cough Mucus clearance is an important primary innate airway clearance with the use of radiolabeled aerosol. Discussing defense mechanism, and our understanding of the key this subject is outside the scope of this review. Moreover, parameters underlying its function has grown rapidly in the studies on mucoactive agents in CF patients, and studies last decade.1,2 Impaired mucus clearance or mucus hyper- on physiotherapy or secretion clearance techniques in secretion are important clinical features in diseases such as (pediatric) lung disease patients have been reviewed by cystic fibrosis (CF), recurrent bronchitis, asthma, and others, and will therefore not be discussed in this review.
    [Show full text]
  • Secretion Properties, Clearance, and Therapy in Airway Disease Bruce K Rubin
    Rubin Translational Respiratory Medicine 2014, 2:6 http://www.transrespmed.com/content/2/1/6 REVIEW Open Access Secretion properties, clearance, and therapy in airway disease Bruce K Rubin Abstract Chronic airway diseases like cystic fibrosis, chronic bronchitis, asthma, diffuse panbronchiolitis, and bronchiectasis are all associated with chronic inflammation. The airway mucosa responds to infection and inflammation in part by surface mucous (goblet) cell and submucosal gland hyperplasia and hypertrophy with mucus hypersecretion. Products of inflammation including neutrophil derived DNA and filamentous actin, effete cells, bacteria, and cell debris all contribute to mucus purulence and, when this is expectorated it is called sputum. Mucus is usually cleared by ciliary movement, and sputum is cleared by cough. These airway diseases each are associated with the production of mucus and sputum with characteristic composition, polymer structure, and biophysical properties. These properties change with the progress of the disease making it possible to use sputum analysis to identify the potential cause and severity of airway diseases. This information has also been important for the development of effective mucoactive therapy to promote airway hygiene. Review cells as well. Epithelial cells produce much of the periciliary Introduction fluid layer by active ion transport [9]. Mucus clearance is a primary defense mechanism of the Mucus is usually cleared by airflow and ciliary inter- lung. Mucus is a barrier to airway water loss and microbial actions while sputum is primarily cleared by cough. Se- invasion and it is essential for the clearance of inhaled foreign cretion clearance depends upon mucus properties such matter [1]. Mucus is a viscoelastic gel consisting of water and as viscoelasticity and adhesiveness, serous fluid properties, high molecular weight glycoproteins, called mucins, mixed and ciliary function.
    [Show full text]
  • (51) International Patent Classification: A61K 8/66 (2006.01) A61Q 11/00
    ( (51) International Patent Classification: A61K 8/66 (2006.01) A61Q 11/00 (2006.01) (21) International Application Number: PCT/EP20 19/08 1186 (22) International Filing Date: 13 November 2019 (13. 11.2019) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 18206133.3 14 November 2018 (14. 11.2018) EP (71) Applicant: NOVOZYMES A/S [DK/DK]; Krogshoejvej 36, 2880 Bagsvaerd (DK). (72) Inventors: DURHUUS, Thomas, Thomasen; Krogshoe¬ jvej 36, 2880 Bagsvaerd (DK). PALMEN, Lorena, Gonzalez,; Krogshoejvej 36, 2880 Bagsvaerd (DK). REISER, Anna, Verena,; Krogshoejvej 36, 2880 Bagsvaerd (DK). STREICHER, Werner, W,; Krogshoe¬ jvej 36, 2880 Bagsvaerd (DK). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available) : ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,094,568 B2 Kozlowski Et Al
    US007094568B2 (12) United States Patent (10) Patent No.: US 7,094,568 B2 Kozlowski et al. (45) Date of Patent: Aug. 22, 2006 (54) METHOD FOR PRODUCING PROTEINS WO WO O1, 57198 A3 2, 2002 TAGGED AT THE N- OR C-TERMINUS (75) Inventors: Roland Kozlowski, Babraham (GB); OTHER PUBLICATIONS Michael B. McAndrew, Babraham (GB); Jonathan Michael Blackburn, Bordini, E., and Hamdan, M., “Investigation of Some Covalent and Cambridge (GB); Michelle Anne Noncovalent Complexes by Matrix-assisted Laser Desorption/Ion Mulder, Capetown (ZA); Mitali ization Time-of-flight and Electrospray Mass Spectrometry.” Rapid Commun. Mass Spectrom. 13:1143-1151, John Wiley & Sons, Ltd. Samaddar, Hyderabad (IN) (1999). Cai, J., et al., “Functional Expression of Multidrug Resistance (73) Assignee: Sense Proteomic Ltd., (GB) Protein 1 in Pichia pastoris.” Biochemistry 40:8307-8316, Ameri can Chemical Society (Jun. 2001). (*) Notice: Subject to any disclaimer, the term of this DeRisi, J., et al., “Use of a cDNA microarray to analyse gene patent is extended or adjusted under 35 expression patterns in human cancer,” Nat. Genet. 14:457-460, U.S.C. 154(b) by 477 days. Nature Publishing Co. (1996). Doellgast, G.J., et al., “Sensitive Enzyme-Linked Immunosorbent (21) Appl. No.: 10/114,334 Assay for Detection of Clostridium botulinum Neurotoxins A, B, and E Using Signal Amplification via Enzyme-Linked Coagulation (22) Filed: Apr. 3, 2002 Assay.” J. Clin. Microbiol. 3 1:2402-2409, American Society for Microbiology (1993). (65) Prior Publication Data Giuliani, C.D., et al., “Expression of an active recombinant lysine US 2003 FOOT3811 A1 Apr. 17, 2003 49 phospholipase A myotoxin as a fusion protein in bacteria.” Toxicon 39:1595-1600, Elsevier Science Ltd.
    [Show full text]
  • Letters to Nature
    letters to nature Received 7 July; accepted 21 September 1998. 26. Tronrud, D. E. Conjugate-direction minimization: an improved method for the re®nement of macromolecules. Acta Crystallogr. A 48, 912±916 (1992). 1. Dalbey, R. E., Lively, M. O., Bron, S. & van Dijl, J. M. The chemistry and enzymology of the type 1 27. Wolfe, P. B., Wickner, W. & Goodman, J. M. Sequence of the leader peptidase gene of Escherichia coli signal peptidases. Protein Sci. 6, 1129±1138 (1997). and the orientation of leader peptidase in the bacterial envelope. J. Biol. Chem. 258, 12073±12080 2. Kuo, D. W. et al. Escherichia coli leader peptidase: production of an active form lacking a requirement (1983). for detergent and development of peptide substrates. Arch. Biochem. Biophys. 303, 274±280 (1993). 28. Kraulis, P.G. Molscript: a program to produce both detailed and schematic plots of protein structures. 3. Tschantz, W. R. et al. Characterization of a soluble, catalytically active form of Escherichia coli leader J. Appl. Crystallogr. 24, 946±950 (1991). peptidase: requirement of detergent or phospholipid for optimal activity. Biochemistry 34, 3935±3941 29. Nicholls, A., Sharp, K. A. & Honig, B. Protein folding and association: insights from the interfacial and (1995). the thermodynamic properties of hydrocarbons. Proteins Struct. Funct. Genet. 11, 281±296 (1991). 4. Allsop, A. E. et al.inAnti-Infectives, Recent Advances in Chemistry and Structure-Activity Relationships 30. Meritt, E. A. & Bacon, D. J. Raster3D: photorealistic molecular graphics. Methods Enzymol. 277, 505± (eds Bently, P. H. & O'Hanlon, P. J.) 61±72 (R. Soc. Chem., Cambridge, 1997).
    [Show full text]